ReShape Lifesciences (RSLS) Stock Price, News & Analysis

Company Overview

ReShape Lifesciences Inc. provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus. It is also involved in developing ReShape Obalon Balloon System, consists of a swallowable capsule that tracks and displays the location of the balloon during placement; and ReShape Diabetes Bloc-Stim Neuromodulation (DBSN) device, a technology that is in development for the treatment of type 2 diabetes mellitus. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $0.40 to $0.46
• 50-Day Range: $0.31 to $1.59
• 52-Week Range: $0.30 to $29.00
• Volume: 1.47 million shs
• Average Volume: 4.51 million shs
• Market Capitalization: $4.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

ReShape Lifesciences Stock Analysis - MarketRank™

ReShape Lifesciences scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ReShape Lifesciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of ReShape Lifesciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ReShape Lifesciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ReShape Lifesciences has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.26% of the float of ReShape Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

ReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ReShape Lifesciences has recently increased by 51.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ReShape Lifesciences does not currently pay a dividend.

Dividend Growth

ReShape Lifesciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.26% of the float of ReShape Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

ReShape Lifesciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ReShape Lifesciences has recently increased by 51.01%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.49

News Sentiment

ReShape Lifesciences has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for ReShape Lifesciences this week, compared to 1 article on an average week.

Search Interest

Only 9 people have searched for RSLS on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

6 people have added ReShape Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ReShape Lifesciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of ReShape Lifesciences is held by insiders.

Percentage Held by Institutions

Only 22.06% of the stock of ReShape Lifesciences is held by institutions.

RSLS Stock Analysis - Frequently Asked Questions

How have RSLS shares performed this year?

ReShape Lifesciences' stock was trading at $4.46 at the beginning of 2025. Since then, RSLS stock has decreased by 90.7% and is now trading at $0.4170.
View the best growth stocks for 2025 here.

How were ReShape Lifesciences' earnings last quarter?

ReShape Lifesciences Inc. (NASDAQ:RSLS) issued its earnings results on Friday, April, 4th. The medical device company reported ($1.89) earnings per share for the quarter, topping the consensus estimate of ($4.06) by $2.17. The medical device company had revenue of $1.81 million for the quarter, compared to the consensus estimate of $3.17 million. ReShape Lifesciences had a negative net margin of 86.36% and a negative trailing twelve-month return on equity of 179.83%.
Read the conference call transcript.

When did ReShape Lifesciences' stock split?

Shares of ReShape Lifesciences reverse split before market open on Monday, September 23rd 2024. The 1-58 reverse split was announced on Thursday, September 19th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of ReShape Lifesciences?

Shares of RSLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ReShape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ReShape Lifesciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Digital Turbine (APPS), Nano Dimension (NNDM), CrowdStrike (CRWD) and

Company Calendar

• Last Earnings: 4/04/2025
• Today: 5/06/2025
• Next Earnings (Estimated): 5/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Health Care Equipment
• Current Symbol: NASDAQ:RSLS
• CIK: 1371217
• Web: www.reshapelifesciences.com
• Phone: (949) 429-6680
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($13.72)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,390,000.00
• Net Margins: -86.36%
• Pretax Margin: -85.56%
• Return on Equity: -179.83%
• Return on Assets: -91.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 0.60

Sales & Book Value

• Annual Sales: $8.01 million
• Price / Sales: 0.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.49 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 11,276,000
• Free Float: 729,000
• Market Cap: $4.74 million
• Optionable: Not Optionable
• Beta: 1.48